Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

Condition:   COVID-19 Interventions:   Biological: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells);   Biological: Placebo Sponsors:   Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.;   Hunan Provincial Center for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials